Understanding Financial Toxicity in Myelofibrosis
Addressing financial toxicity associated with myelofibrosis treatment, Dr Mahmoudjafari discusses cost considerations and how lower WAC products can benefit patients.
EP: 1.Myelofibrosis Overview: US Incidence, Prognosis, and Patient Presentation
EP: 2.Unmet Needs in Myelofibrosis: Key Challenges in Disease Management
EP: 3.Impact of Myelofibrosis on Quality of Life: Key Clinical Features
EP: 4.Primary Management Goals and Importance of Risk Stratification in Myelofibrosis
EP: 5.JAK Inhibitors and Myelofibrosis Management: A Review of Current Treatments
EP: 6.Key Patient Factors Guiding Myelofibrosis Treatment Selection
EP: 7.Key Outcomes for Monitoring Myelofibrosis Treatment Response
EP: 8.Strategies for Treatment Optimization and Adverse Event Reduction in Myelofibrosis
EP: 9.Understanding Financial Toxicity in Myelofibrosis
EP: 10.Advancing Myelofibrosis Treatment: What Lies Ahead
Video content above is prompted by the following:
- From a patient perspective, what are some financial toxicity considerations that should be considered, particularly for those patients with co-insurance or high deductible health plan pharmacy benefit design?
- For patients enrolled in high deductible health plans, how do lower WAC products affect their out-of-pocket expenses?
- For patients enrolled in high deductible health plans, how do lower WAC products affect their out-of-pocket expenses?
Duvelisib Shows Promise in Treating Relapsed/Refractory CLL/SLL: Insights from the DUO Trial
June 17th 2024The recent DUO trial, a global Phase III study, compared the efficacy and safety of duvelisib, an oral PI3K inhibitor, with ofatumumab, an anti-CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously undergone at least one therapy.
Read More
The Role of Pharmacogenomics in Reducing Racial Disparities in Pediatric AML Treatment Outcomes
May 20th 2024A new study in JAMA Network Open suggests that disparities in outcomes between Black and White children with acute myeloid leukemia may be due to differences in pharmacogenomics, which is how genes affect drug responses.
Read More
